REPLIMUNE GROUP, INC. Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount
REPLIMUNE GROUP, INC. (REPL) reported Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount of $788.00 thousand for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxExemptIncome · last filed 2026-06-29
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2026 was $788.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount 12 month |
|---|---|
| 2026-03-31 | $788.00K 10-K · filed 2026-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |